ci 949 has been researched along with calcimycin in 1 studies
| Studies (ci 949) | Trials (ci 949) | Recent Studies (post-2010) (ci 949) | Studies (calcimycin) | Trials (calcimycin) | Recent Studies (post-2010) (calcimycin) |
|---|---|---|---|---|---|
| 9 | 0 | 0 | 11,946 | 40 | 444 |
| Protein | Taxonomy | ci 949 (IC50) | calcimycin (IC50) |
|---|---|---|---|
| XBP1 | Homo sapiens (human) | 1.41 | |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | 0.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adolphson, RL; Chestnut, JC; Conroy, MC; Kennedy, JA; Thueson, DO; Wright, CD | 1 |
1 other study(ies) available for ci 949 and calcimycin
| Article | Year |
|---|---|
Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949.
Topics: Basophils; Calcimycin; Dose-Response Relationship, Drug; Histamine Antagonists; Histamine Release; Humans; Immunoglobulin E; Indoles; Lung; Mast Cells; SRS-A; Tetradecanoylphorbol Acetate; Tetrazoles; Thromboxane B2 | 1990 |